There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CureVac (CVAC – Research Report) and Evolus (EOLS – Research Report) with bullish sentiments.
CureVac (CVAC)
Leerink Partners analyst Mani Foroohar maintained a Buy rating on CureVac on December 20. The company’s shares closed last Friday at $4.06, close to its 52-week low of $3.41.
According to TipRanks.com, Foroohar is a 2-star analyst with an average return of
Currently, the analyst consensus on CureVac is a Moderate Buy with an average price target of $13.35, implying a 226.4% upside from current levels. In a report issued on December 19, Jefferies also maintained a Buy rating on the stock with a $21.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Evolus (EOLS)
In a report issued on December 20, Marc Goodman from Leerink Partners maintained a Buy rating on Evolus. The company’s shares closed last Friday at $9.96.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus with a $22.25 average price target, representing a 122.5% upside. In a report issued on December 17, Mizuho Securities also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CVAC:
- CureVac price target lowered to $6.40 from $8 at BofA
- CureVac announces German Federal Patent Court decision in BioNTech litigation
- CureVac to appeal patent decision before German Federal Court of Justice
- Germany’s patent court invalidates CureVac patent, Reuters reports
- CVAC Upcoming Earnings Report: What to Expect?
